Gonadotropin chorionic, lyophilisate 1500 units 5 pcs

• The drug has gonadotropic effect, mainly luteinizing;

• Stimulates the synthesis of sex hormones in the ovaries and testicles;

• Stimulates ovulation in women and spermatogenesis in men;

• Stimulates the development of the genitals and secondary sexual characteristics.

.

Indications

Pituitary gland hypofunction in men and women caused by disorders of hypothalamus and pituitary gland activity.
In women: anovulatory infertility, insufficiency of the corpus luteum (in the presence of ovarian estrogenic function), induction of superovulation by assisted reproductive techniques, habitual miscarriage, threatening spontaneous miscarriage.

In men: hypogenitalism, eunuchoidism, testicular hypoplasia, cryptorchidism, adiposogenital syndrome, pituitary dwarfism, sexual infantilism, oligoasthenospermia, azoospermia.

For the purpose of differential diagnosis of cryptorchidism and anarchism in boys and for evaluation of testicular function in hypogonadotropic hypogonadism.

Active ingredient

Composition

Active substance

Chorionic gonadotropin 5000 units;

Associates

Mannitol (mannitol).

Five vials of the preparation in a carton box and five ampules of 1 ml of 0.9% sodium chloride solution for injection in a carton box, together with the instructions for administration of the preparation and the solvent are placed in a carton package.

How to take, the dosage

The drug is administered intramuscularly.

In women for induction of ovulation – a single dose of 5000-10000 IU, for stimulation of the corpus luteum function – 1500-5000 IU on days 3-6-9 after ovulation.

For induction of superovulation during assisted reproductive interventions – up to 10000 units once after induction of multiple follicle growth, which is achieved by stimulation according to the established scheme. The egg collection is carried out 34-36 h after the introduction.

In case of habitual abortion the administration is started as soon as the pregnancy is diagnosed (but not later than within 8 weeks) and is continued till the 14th week of pregnancy inclusive: on the 1st day – 10000 IU, further in 5000 IU twice a week.

With threat of spontaneous miscarriage (if symptoms appeared in the first 8 weeks of pregnancy) – 10000 IU initially, then 5000 IU twice a week until the 14th week of pregnancy inclusive.
In case of delayed pubertal development of boys – 3000-5000 ME once a week for at least 3 months.

For men – 500-2000 IU once a day, 2 or 3 times a week for 1.5-3 months.

For hypogonadotropic hypogonadism: 1500-6000 units (in combination with menotropins) once a week. For the differential diagnostics of cryptorchidism and anarchism in boys and for evaluation of testicular function in hypogonadotropic hypogonadism: once- 5000 units.

In case of cryptorchidism: up to 6 years of age – 500-1000 units 2 times per week for 6 weeks; over 6 years of age – 1500 units 2 times per week for 6 weeks.

In idiopathic normogonadotropic oligospermia – 5000 units weekly for 3 months along with menotropins. In oligo- and asthenospermia caused by relative androgen insufficiency – 2500 IU every 5 days or 10000 IU once every 2 weeks during 3 months.

Interaction

Gonadotropin chorionic is used in combination with gonadotropin menopause in the treatment of infertility.

Special Instructions

The drug is ineffective in men with high levels of follicle stimulating hormone (FSH).

Preterm puberty may occur in adolescent males with physical and sexual development disorders if prolonged treatment or high doses are used.

Unreasonably prolonged use of the drug in cryptorchidism, especially if surgical intervention is indicated, can lead to degeneration of the sex glands.

Inhibition of FSH production due to stimulation of androgen and estrogen production promotes atrophy of the seminal tubules.
Prolonged administration may lead to the formation of antibodies to the drug.
Increases the likelihood of multiple pregnancies.

Possible erroneous results when using a pregnancy test during treatment with the drug and for 7 days after discontinuation.

Contraindications

Hypersensitivity to the components of the drug, pituitary tumor, hormone-active tumors of reproductive glands (including androgen-dependent), absence of glands (congenital or after surgery), early onset of menopause, thrombophlebitis, lactation, ovarian cancer, hypothyroidism, adrenal insufficiency, hyperprolactinemia, fallopian tubes obstruction.

With caution: adolescence, coronary heart disease, arterial hypertension, chronic renal failure, bronchial asthma, migraine.

Side effects

Local reactions (pain at the injection site, hyperemia);

Allergic reactions;

Headache;

Increased fatigue;

Irritability;

Anxiety;

Depression;

Suppression of gonadotropic function of the pituitary gland.

In men: fluid retention, edema, increased sensitivity of the breast nipples, gynecomastia, enlargement of the testicles in the inguinal canal (in cryptorchidism). As a result of long-term use of the drug in men a decrease in the number of sperm cells in the ejaculate was found.

Overdose

In overdose of the drug in women may result in ovarian hyperstimulation syndrome with an increase in their size due to ovarian cysts with the risk of their rupture, the appearance of ascites and hydrothorax.

The occurrence may be indicated by symptoms such as a feeling of tension and pain in the abdomen, vomiting, diarrhea, difficulty breathing, increased body weight.

The treatment is symptomatic.